Cellular Therapy for Solid Tumors: Current Status and Future Directions

Disclosure(s):

Michael Caligiuri, MD: Beigene: Ownership Interest (Ongoing); Breakthrough Exchange Holdings, LLC: Advisor (Ongoing), Consultant (Ongoing); CBMG: Advisor (Ongoing), Consultant (Ongoing); CytoImmune Therapeutics: Executive Role (Ongoing); Cytovia: Advisor (Ongoing), Consultant (Ongoing); Imugene: Advisor (Terminated), Consultant (Terminated); MBQ Pharma: Advisor (Ongoing); OncoC4: Advisor (Ongoing), Consultant (Ongoing); Origin: Advisor (Ongoing), Consultant (Ongoing); Precision Technologies: Executive Role (Ongoing)